137 related articles for article (PubMed ID: 37914255)
1. Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients.
Tyson MD; Abouassaly R; Durant A; Smith AB; Seemann K; Shoskes DA
Urol Pract; 2024 Jan; 11(1):54-60. PubMed ID: 37914255
[TBL] [Abstract][Full Text] [Related]
2. Urinary Analysis of
Lotan Y; Raman JD; Konety B; Daneshmand S; Schroeck F; Shariat SF; Black P; de Lange M; Asroff S; Goldfischer E; Efros M; Chong KT; Huang E; Chua HL; Wu QH; Yeow S; Lau W; Yong J; Eng M
J Urol; 2023 Apr; 209(4):762-772. PubMed ID: 36583640
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
Lotan Y; Daneshmand S; Shore N; Black P; Scarpato KR; Patel A; Lough T; Shoskes DA; Raman JD
J Urol; 2024 Jul; 212(1):41-51. PubMed ID: 38700731
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.
Konety B; Shore N; Kader AK; Porten S; Daneshmand S; Lough T; Lotan Y
Eur Urol; 2019 Aug; 76(2):238-243. PubMed ID: 31103391
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma.
Darling D; Luxmanan C; O'Sullivan P; Lough T; Suttie J
Adv Ther; 2017 May; 34(5):1087-1096. PubMed ID: 28341930
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.
Koya M; Osborne S; Chemaslé C; Porten S; Schuckman A; Kennedy-Smith A
BMC Urol; 2020 Feb; 20(1):12. PubMed ID: 32046687
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
Gold SA; Kenigsberg AP; Lotan Y
J Urol; 2022 Jan; 207(1):52-60. PubMed ID: 34428924
[TBL] [Abstract][Full Text] [Related]
8. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
Raman JD; Kavalieris L; Konety B; Porten S; Daneshmand S; Lotan Y; Loo R
J Urol; 2021 Dec; 206(6):1380-1389. PubMed ID: 34348469
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.
Lough T; Luo Q; Luxmanan C; Anderson A; Suttie J; O'Sullivan P; Darling D
BMC Urol; 2018 Mar; 18(1):18. PubMed ID: 29523118
[TBL] [Abstract][Full Text] [Related]
10. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.
Boman H; Hedelin H; Jacobsson S; Holmäng S
J Urol; 2002 Nov; 168(5):1955-9. PubMed ID: 12394684
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy.
Davidson PJ; McGeoch G; Shand B
N Z Med J; 2019 Jun; 132(1497):55-64. PubMed ID: 31220066
[TBL] [Abstract][Full Text] [Related]
12. Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study.
Chai CA; Yeoh WS; Rajandram R; Aung KP; Ong TA; Kuppusamy S; Nazran A; Kumaran K; Razack AHA; Teoh JY
Front Surg; 2021; 8():659292. PubMed ID: 34055868
[No Abstract] [Full Text] [Related]
13. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
14. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
de Jong JJ; Pijpers OM; van Kessel KEM; Boormans JL; Van Criekinge W; Zwarthoff EC; Lotan Y
Eur Urol Oncol; 2023 Apr; 6(2):183-189. PubMed ID: 36089502
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
16. Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
Li KD; Chu CE; Patel M; Meng MV; Morgan TM; Porten SP
Urol Oncol; 2023 Jul; 41(7):326.e1-326.e8. PubMed ID: 36868882
[TBL] [Abstract][Full Text] [Related]
17. Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer.
Chuttiangtum A; Udomthavornsuk B; Chumworathayi B
Asian Pac J Cancer Prev; 2012; 13(10):4931-3. PubMed ID: 23244084
[TBL] [Abstract][Full Text] [Related]
18. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
[TBL] [Abstract][Full Text] [Related]
19. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
